A detailed history of Corsair Capital Management, L.P. transactions in Achilles Therapeutics PLC stock. As of the latest transaction made, Corsair Capital Management, L.P. holds 20,000 shares of ACHL stock, worth $19,600. This represents 0.0% of its overall portfolio holdings.

Number of Shares
20,000
Holding current value
$19,600
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$0.7 - $1.04 $14,000 - $20,800
20,000 New
20,000 $20,000

Others Institutions Holding ACHL

About Achilles Therapeutics plc


  • Ticker ACHL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,774,000
  • Market Cap $40M
  • Description
  • Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in ...
More about ACHL
Track This Portfolio

Track Corsair Capital Management, L.P. Portfolio

Follow Corsair Capital Management, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Corsair Capital Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Corsair Capital Management, L.P. with notifications on news.